Drug immunotoxicological approaches with some selected medical products: cyclophosphamide, methylprednisolone, betamethasone, cefoxitine, minor tranquillizers.
Alterations of the normal immune response were estimated in C57B1/6 mice pretreated with cyclophosphamide, methylprednisolone sodium succinate, betamethasone sodium phosphate or cefoxitine as positive controls and three minor tranquillizers: dipotassium chlorazepate, diazepam and meprobamate. The specific immune response against sheep red blood cells (SRBC) was evaluated by numeration of the direct plaque-forming cells (PFC; humoral immunity) and by measurement of the footpad swelling (delayed-type hypersensitivity, DTH). In our experiments, the results with the positive controls were in the same order as those described by others, and at the dose levels used, these three minor tranquillizers did not really alter the specific humoral and cellular immune response against SRBC in the C57B1/6 mice.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000633:toxicity*; D001623:Betamethasone / Q000633:toxicity*; D002440:Cefoxitin / Q000633:toxicity*; D003165:Complement System Proteins / Q000032:analysis; D003520:Cyclophosphamide / Q000633:toxicity*; D006462:Hemolytic Plaque Technique; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007109:Immunity / Q000187:drug effects*; D008297:Male; D008775:Methylprednisolone / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D012756:Sheep
D014151:Anti-Anxiety Agents; D002440:Cefoxitin; D003520:Cyclophosphamide; D003165:Complement System Proteins; D001623:Betamethasone; D008775:Methylprednisolone